BB Biotech Q2 Net Loss Of CHF 87 Mln
July 26 (Reuters) -BB BIOTECH AG BION.S:
A NET LOSS OF CHF 87 MN WAS INCURRED IN Q2 COMPARED TO A NET LOSS OF CHF 13 MN IN PRIOR-YEAR PERIOD
A NET PROFIT OF CHF 173 MN WAS GENERATED DURING FIRST HALF OF 2024 COMPARED TO A NET LOSS OF CHF 267 MN IN SAME PERIOD OF 2023
BB BIOTECH'S SHARES CLOSED PERIOD 12.0% LOWER IN CHF AND 11.3% LOWER IN EUR
BOARD OF DIRECTORS HAS APPOINTED DR. CHRISTIAN KOCH, ONE OF TWO DEPUTY HEADS, AS NEW HEAD OF INVESTMENT MANAGEMENT TEAM EFFECTIVE JANUARY 1, 2025
DR. DANIEL KOLLER, WHO HAS SERVED AS HEAD OF BB BIOTECH'S INVESTMENT MANAGEMENT TEAM SINCE 2010, HAS INFORMED BOARD OF DIRECTORS OF HIS INTENTION TO RETIRE FROM HIS POSITION BY END OF 2024
TOTAL RETURN OF PORTFOLIO WAS -3.5% IN CHF, -2.6% IN EUR AND -3.3% IN USD
FOR FIRST SIX MONTHS OF 2024, TOTAL RETURN FOR BB BIOTECH'S SHARES WAS -2.0% IN CHF AND -4.6% IN EUR
PORTFOLIO PERFORMANCE WAS +7.3% IN CHF, +3.5% IN EUR, AND +0.4% IN USD
OUTLOOK: UPCOMING PRESIDENTIAL ELECTIONS IN USA COULD ALSO INFLUENCE SECTOR, PARTICULARLY THROUGH POSSIBLE CHANGES IN HEALTHCARE POLICY AND DRUG PRICES
OUTLOOK: INTEREST RATE DECISIONS REMAIN A PIVOTAL INFLUENCE ON BIOTECH INVESTMENTS
LEVEL OF INVESTMENT OF 113.5%
SHARE PRICE RETURN IN Q2 OF 2024 WAS -12.0% IN CHF AND -11.3% IN EUR
NET LOSS IN Q2 2024 AMOUNTED TO CHF 87 MN COMPARED TO A NET LOSS OF CHF 13 MN IN PRIOR-YEAR PERIOD
Source text for Eikon: ID:nEQ9RZ8mza
Further company coverage: BION.S
(Gdansk Newsroom)
</body></html>
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
